Asgard Therapeutics
PrivateLast Round
Grant
Mar 11, 2025
Total Funding Raised
$39.85M
Company Overview
Asgard Therapeutics operates in Healthcare & Life Sciences and is based in Lund. Its latest recorded funding round was a Series A round in March 2024.
Asgard Therapeutics is a biotechnology company that develops innovative gene therapy products leveraging direct cell reprogramming for personalized cancer immunotherapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Asgard Therapeutics Comparables
Compare Asgard Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Reprogram Biosciences | 83% | |
| Lokon Pharma | 78% | |
| Qurgen | 78% |
For institutional investors. Book with your work email.
Asgard Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 11, 2025 | ||||
| Series A | Mar 14, 2024 | ||||
| Seed | Nov 9, 2021 | ||||
| Grant | Apr 6, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Asgard Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| Boehringer Ingelheim | Series A, Seed |
| Vinnova | Grant |
| Industrifonden | Series A, Seed |
| Novo Holdings | Series A, Seed |
| RV Invest | Series A |
| Boehringer Ingelheim Venture Fund | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 27, 2026
Oral presentation at ASGCT 2026 showcasing cancer immunotherapy data.
- Apr 27, 2026
Oral presentation at ASGCT 2026 on preclinical data for AT-108.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 4, 2026
Asgard Therapeutics AB and University of Coimbra collaborate with Lund University and Shanghai Cancer Centre on a study linking induced immunogenic niches to tumor control, published on Nov 4th '26.
- attends_eventNov 4, 2026
Asgard Therapeutics AB is to present new AT-108 biomarker data at SITC 2026, including tumor- and blood-based pharmacodynamic biomarkers of AT-108 activity.
For institutional investors. Book with your work email.
Asgard Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Asgard Therapeutics's valuation, stock price, and market status.
Is Asgard Therapeutics a public or private company?
Asgard Therapeutics is a private company.
What is the current stock price of Asgard Therapeutics?
Asgard Therapeutics is a private company, so its shares have no public market price. Caplight tracks Asgard Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Asgard Therapeutics worth (valuation)?
Valuation information for Asgard Therapeutics is not publicly available.
Can I buy Asgard Therapeutics stock?
Asgard Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Asgard Therapeutics's last funding round?
Asgard Therapeutics's most recent funding round was Grant on March 11, 2025.
Who are the main investors in Asgard Therapeutics?
Key investors in Asgard Therapeutics include Boehringer Ingelheim, Industrifonden, Novo Holdings, RV Invest, Boehringer Ingelheim Venture Fund.
Will Asgard Therapeutics IPO soon?
No public IPO plans have been announced for Asgard Therapeutics.
How can I track Asgard Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Asgard Therapeutics's shares on secondary markets.